SaaS entity
All 1 tracked stories fall under one category: earnings. Standard BioTools is most often covered alongside CyTOF, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window.
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Standard BioTools is most often covered alongside CyTOF, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. Source depth averages 2 original sources per story, versus 2.1 across the same-window beat baseline. Standard BioTools appears in 1 tracked SaaS story from February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 SaaS stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Standard BioTools. Shared-story counts are live from our verified record — not editorial picks.
Evolent and Standard BioTools reported strong 2025 revenue growth, with Evolent crossing the $2.6 billion threshold and Standard BioTools achieving its first positive adjusted EBITDA quarter. Both companies are now pivoting toward margin expansion and operational discipline as they enter the 2026 fiscal year.
Standard BioTools is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
